| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_282d8844066f5f683bc2463742373508 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2012-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6fad3e9743ff7ea15fe4bdce0287cee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea4df55ce9df9eb85b7731c73998cda4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb035d223bc65e3c0554d2fd06043450
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9bf00bc9d74f86e43f9f7ed9d5d11410
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e587c061cc4556c5a6ca0caaa9b81146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a45669a50f52812088cf37180877bf5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c4f1b69f3734fe809bd5a93e3183454 |
| publicationDate |
2014-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2734234-A2 |
| titleOfInvention |
Anti-cxcr4 antibodies and methods of use |
| abstract |
The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4. |
| priorityDate |
2011-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |